You can’t turn on the television these days without encountering advertisements for pharmaceuticals. Drug companies are working hard to make names like Emgality, Trulicity and Dupixent as familiar as Camry, Silverado and Explorer.

It’s never been easy to find names that pass muster with the Food and Drug Administration, which aren’t in use by others and still have a little panache. But it’s growing more difficult with each passing year as the pharmaceutical marketplace grows ever more crowded. That’s why short two-syllable names like Prozac and Darvon are mostly relics of the past.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]